| Document |
Document Title |
|
WO/2018/107082A1 |
The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal do...
|
|
WO/2018/104267A1 |
The application generally relates to chloroplast targeting of nuclear-encoded proteins of interest in microalgae. Provided herein are expression cassettes comprising a nucleotide sequence encoding a chloroplast targeting peptide operably...
|
|
WO/2018/106610A1 |
In certain embodiments methods of enriching a population of mammalian hematopoietic stem cells for CD34+/CD38- stem cells are provided. In certain embodiments the methods involve contacting a mammalian hematopoietic tissue sample with a ...
|
|
WO/2018/104473A1 |
The present invention relates to cancer immunotherapy. In particular, provided herein are compositions and methods for improving the efficacy of cell therapies cancer and other diseases.
|
|
WO/2018/106628A1 |
Disclosed herein are methods for the in vitro differentiation of a precursor cell into definitive endoderm, which may further be differentiated into a human colonic organoid (HCO), via modulation of signaling pathways. Further disclosed ...
|
|
WO/2018/106885A1 |
FOXP3+ regulatory T cells (Tregs) can represent powerful adoptive immunotherapies for autoimmune diseases, metabolic diseases, and other chronic inflammatory diseases. The present invention is related to the ability to maintain and expan...
|
|
WO/2018/103406A1 |
A neural stem cell injection is derived from a source of human fetal cerebral cortex and used for treating various brain damages. The neural stem cell injection at least comprises 1×106 neural stem cells, in which the neural stem cells ...
|
|
WO/2018/104325A1 |
The present invention relates to the use of peptide compounds for promoting survival and/or growth and/or differentiation of progenitor cells or stem cells.
|
|
WO/2018/105255A1 |
A method for producing a cell aggregate structure comprises: a supply step of holding a cell agglutinate clump 2 on a holding section H composed of multiple pins 16 that are provided so as to stand in a culture vessel 3; a culturing step...
|
|
WO/2018/106870A1 |
Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.
|
|
WO/2018/105805A1 |
The present invention relates to a method for isolating an islet from a newborn pig and, specifically, to a method for isolating an islet of a newborn pig, the method comprising the steps of: (a) extracting an islet from a newborn pig; (...
|
|
WO/2018/103654A1 |
An artificial ovary and a preparation and application of the same. The artificial ovary comprises a biocompatible frame, follicular cells, and a coating mixed liquid, wherein the coating mixed liquid covers the outside of the follicular ...
|
|
WO/2018/107135A1 |
A method for isolating self-renewable stem cells from pluripotent stem cells (embryonic or induced) by treating the pluripotent stem cells with a combination of epidermal growth factor and basic growth factor, wherein upon treatment, the...
|
|
WO/2018/103630A1 |
Disclosed are a hybridoma cell strain C1 for secreting an anti-paromomycin monoclonal antibody and the use thereof, belonging to the technical field of immunochemistry. A murine monoclonal cell strain C1 has been prepared through the con...
|
|
WO/2018/107157A1 |
A method of modulating transdifferentiation of chondrocytes to osteoblast includes administering to the chondrocytes an agent that modulates GP130 receptor signaling and expression of at least one of Sox2, Oct4, or Nanog of the chondrocy...
|
|
WO/2018/106849A1 |
Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-base...
|
|
WO/2018/106820A1 |
The present disclosure provides methods of promoting proliferation of a pancreatic cell. The methods are useful for the treatment of diabetes and other diseases characterized by impaired glucose tolerance.
|
|
WO/2018/103734A1 |
Disclosed are a chimeric antigen receptor (CAR) and the use thereof and a preparation method therefor, a T-cell containing the chimeric antigen receptor, a nucleic acid sequence encoding the chimeric antigen receptor, a vector comprising...
|
|
WO/2018/105078A1 |
A cell culture method is one for culturing cells using a culture vessel equipped with a first vessel and a second vessel having a liquid pass and housed inside of the first vessel, wherein the liquid pass is so configured that a liquid c...
|
|
WO/2018/103501A1 |
Provided are a human PD-1 knockdown siRNA, a recombinant expression CAR-T vector, a preparation method thereof, and an application of the same. A PD-1 knockdown siRNA expression cassette and an siRNA expression product thereof can be app...
|
|
WO/2018/106892A1 |
The invention features compositions and methods for identifying orthogonal transcriptional switches derived from Tet repressor homologs for Saccharomyces cerevishiae regulated by 2,4-diacetylphloroglucinol (DAPG) and other ligands.
|
|
WO/2018/106804A1 |
The disclosure provides a new and distinct clonal line plant of Solanum tuberosum L. named KI969 and characterized by elevated levels of proteinase inhibitor II (PI2). Further disclosed are phenotypic characteristics of KI969 and methods...
|
|
WO/2018/106536A1 |
Provided are methods for making highly dedifferentiated and stem-like human cells from human umbilical vein endothelial cells (HUVECs) ectopically expressing integrin β3. Also provided are methods for making ectoderm, mesoderm, and endo...
|
|
WO/2018/104909A2 |
Provided herein are methods and compositions for modulating T-cell activity by altering DNA methylation status. Altering the methylation status of CD8+ T cells can prevent T-cell exhaustion and maintain effector functions during sustaine...
|
|
WO/2018/106997A1 |
The present disclosure provides compositions and methods employing stem cell-derived amnion tissue. In some embodiments, compositions (e.g., scaffolds and devices) and methods of generating amnion-like tissues from hPSCs are provided. In...
|
|
WO/2018/106803A1 |
The disclosure provides a new and distinct clonal line plant of Solanum tuberosum L. named KI964 and characterized by elevated levels of proteinase inhibitor II (Pl2). Further disclosed are phenotypic characteristics of KI964 and methods...
|
|
WO/2018/106414A1 |
This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.
|
|
WO/2018/105777A1 |
The present invention relates to a three-dimensional micro-environment structure for controlling cell behavior, a three-dimensional surface for controlling cell behavior, and a method for manufacturing an array and a three-dimensional mi...
|
|
WO/2018/106732A1 |
Provided are methods for genetically engineering cells, including cells for use in connection with genetic engineering. In some embodiments, the provided methods including transduction of cells by incubation with a retroviral vector part...
|
|
WO/2018/105560A1 |
The purpose of the present invention is to provide a novel technique for controlling the blood-brain barrier. An antibody of which the epitope is a region located in an extracellular domain of Claudin 5 protein.
|
|
WO/2018/107064A1 |
Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.
|
|
WO/2018/106470A1 |
The present invention is drawn to compositions and methods for improving transformation frequency. The compositions, synthetic selectable marker genes, are used in transformation methods and result in increased transformation frequency.
|
|
WO/2018/104324A1 |
A polymer hydrogel comprising a polymer formed by the crosslinking reaction of a polymeric unit A according to formula (I), with a crosslinking unit B according to formula (II), and water, wherein n = 100 - 10,000, preferable 250 - 2500,...
|
|
WO/2018/102881A1 |
The present invention relates to culture media for oocytes and uses thereof. Specifically, media for culturing an oocyte in vitro are disclosed, wherein said media comprise granulocyte macrophage-colony stimulating factor (GM-CSF). The p...
|
|
WO/2018/102547A1 |
Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill TAG-72-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK)...
|
|
WO/2018/101466A1 |
The present invention relates to a method for producing endothelial cells, in which a step (a) of inducing a mesoblastic cell mass containing endothelial progenitor cells from pluripotent stem cells without forming embryoid bodies and a ...
|
|
WO/2018/100803A1 |
The purpose of the present invention is to provide a novel fluorescent protein. This FRET-type fluorescent protein complex is characterized by the following: including a first fluorescent protein and a second fluorescent protein; the fir...
|
|
WO/2018/102567A1 |
The present disclosure provides a method of treating cancer by immune checkpoint blockade, or selecting patients for treatment with immune checkpoint blockers, by detecting tumors with high levels of T-lymphocytes with low levels of acti...
|
|
WO/2018/101723A1 |
One embodiment of the present invention provides novel functionally enhanced mesenchymal progenitor cells overexpressing epidermal growth factor receptor (EGF-R) in comparison with mesenchymal stem cells (MSCs), and downexpressing cluste...
|
|
WO/2018/101782A1 |
The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory factors CD32, CD80, CD8...
|
|
WO/2018/100580A1 |
The present disclosure provides a process and system for generating a 3D scaffold. The process comprises (a) adding into a receptacle (106) a layer of a gelatinous thermosensitive hydrogel; (b) directing a focused heat onto portions of t...
|
|
WO/2018/098597A1 |
Methods are disclosed for producing populations of cardiomyocytes from pluripotent stem cells. Populations may be enriched for either atrial or ventricular cardiomyocytes and the resulting ventricular population may be essentially free o...
|
|
WO/2018/098553A1 |
A method of making an antibody in plants that binds to ricin is described. The method comprises (a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light c...
|
|
WO/2018/101796A1 |
The present invention relates to an artificial antigen-presenting cell prepared from HLA-null cell line using a multiplex CRISPR-Cas9 system and the use thereof and, more particularly, to a novel artificial antigen-presenting cell which ...
|
|
WO/2018/100584A1 |
A process for the preparation of chondrocyte cell suspension and its use in defect site of knee or ankle or shoulder or wrist or elbow or hip of subject.
|
|
WO/2018/102202A1 |
An in vitro microfluidic gut-on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic culture is descr...
|
|
WO/2018/101270A1 |
The purpose of the present invention is to provide, with respect to the cold storage of mouse sperm, a cold storage solution and a storage method that enable cold storage for a longer period of time than the prior art. The present invent...
|
|
WO/2018/100212A1 |
The present invention relates to a method for obtaining neural stem cells and neural progenitor cells (NSC/NPC) from ovarian cortical tissue of pre-pubescent female mammals, without needing to add factors for inducing and/or expanding th...
|
|
WO/2018/102761A1 |
A method for preparing T cell populations for use in CAR T cell therapy and other immune cell therapies is described.
|
|
WO/2018/102775A1 |
Disclosed herein is a novel gene signature of metastatic cancer cells and a novel three-dimensional (3D) culture system for use in improved methods of predicting metastasis or prognosis in cancer. Accordingly, described herein are method...
|
